Are peptides legal? What each peptide's status actually means

Every page on our network that covers an unapproved or partly approved substance carries one short status line, and every one of those lines links here. This page explains what the lines mean, lists them by substance, and notes what changed in 2026. It is a plain-language reference, checked against the FDA record as of October 12, 2026 and refreshed monthly. It is not legal advice, and state rules can add to the federal picture.

Are peptides legal in the US?

There is no single answer, because “peptide” covers three very different things. A few are active ingredients in FDA-approved medicines, such as tesamorelin in Egrifta. Many of the peptides discussed online are not FDA-approved at all and reach people either as compounded prescriptions or as products labeled for research only. A third group, like retatrutide, is still in clinical trials. The FDA’s own plain statement on the middle group is that “compounded drugs are not FDA-approved”, which means the agency does not check their safety, effectiveness or quality before they are sold. So the useful question is not “are peptides legal” but “which bucket is this one in”, and the table below answers that substance by substance. Federal status is only half of it: states set their own telehealth and pharmacy rules on top, and PeptideAgent keeps state-by-state peptide law summaries that cite each state’s statute or board rule.

Peptide status by substance (as of October 12, 2026)

Each row is the exact one-line status our pages use for that substance. Names link to our overview where one exists.

Where these lines come from: the FDA’s Category 2 page lists BPC-157, TB-500, MOTS-c, semax, epitalon, CJC-1295, ipamorelin, thymosin alpha-1, selank, injectable GHK-Cu and melanotan II among nominated substances that were withdrawn, and the federal list of bulk substances that pharmacies may compound from, 21 CFR 216.23, still names six substances, none of them a peptide. The Egrifta label limits tesamorelin to reducing excess abdominal fat in adults with HIV and lipodystrophy, and says it is not indicated for weight loss. Sildenafil is approved as Viagra for erectile dysfunction, and oral minoxidil tablets are labeled only for a specific kind of hard-to-control high blood pressure. Retatrutide’s maker calls it “an investigational molecule that cannot be legally sold or marketed for human use” and plans its US filing for the first quarter of 2027.

What do the words in a status line mean?

Five phrases do almost all the work, and each has a specific meaning.

• FDA-approved. The FDA reviewed a specific product for a specific use. Approval of one product does not cover other uses or other versions of the same ingredient, which is why the tesamorelin line names Egrifta.
• Not FDA-approved / compounded prescription. A pharmacy mixes the drug for an individual prescription. FDA says it does not verify the safety, effectiveness or quality of compounded drugs before they are marketed. Federal law lets a 503A pharmacy compound from a bulk ingredient only if it has a USP or NF monograph, is a component of an FDA-approved drug, or appears on FDA’s 503A bulks list.
• Off-label. FDA’s consumer page describes this as using an approved drug “for a disease or medical condition that it is not approved to treat”, or in a different form or dose. Oral minoxidil for hair loss is the example on our pages.
• Investigational. The drug is still being tested in clinical trials and has not been submitted for, or has not received, approval. Retatrutide is the current example.
• Research use only. A labeling claim that a product is for lab work, not people. In a March 31, 2026 warning letter, FDA said that despite labels reading “laboratory research purposes only” and “not for human consumption,” the seller’s website showed the products were intended as drugs for human use.

What changed for peptides in 2026?

The outlook moved, but the status of each substance did not. Three things happened, in order:

1. April 2026. The FDA’s Category 2 page, the interim list of substances it flags as possible safety risks in compounding, was updated to show a group of peptides, including BPC-157, TB-500, MOTS-c, epitalon and semax, in a table of nominations that were withdrawn. Ipamorelin is still listed there under the separate 503B policy for outsourcing facilities.
2. July 23-24, 2026. An FDA advisory committee met on seven peptides. ABC News reported that it voted to recommend adding BPC-157, KPV, TB-500, MOTS-c, epitalon and semax to the list pharmacies may compound from, and that the vote is non-binding and still needs FDA sign-off.
3. Since then. As of October 12, 2026 the bulks list in 21 CFR 216.23 has not changed, so the status lines above stay as written until FDA acts. PeptideAgent’s peptide regulatory tracker logs each dated FDA, PCAC, Federal Register and WADA action newest first, with a link to the primary source.

Is BPC-157 legal?

BPC-157 is not FDA-approved, and some telehealth providers sell it as a compounded prescription. It was one of the six peptides the advisory committee reportedly recommended in July 2026, but no rule has followed yet. Athletes have a separate issue: the US Anti-Doping Agency says BPC-157 is prohibited under the WADA list’s S0 category of non-approved substances. For what it is, how people use it and what the mostly preclinical research shows, see our BPC-157 overview.

Did RFK Jr. make peptides legal?

No federal rule changed any peptide’s status in 2026. The story traces to a podcast: Gizmodo reported on March 2, 2026 that Health and Human Services Secretary Robert F. Kennedy Jr. told Joe Rogan the FDA would reportedly consider taking around 14 peptides off its restricted list. The real steps were the April Category 2 update and the July advisory vote described above, and neither one is a rule. Two peptides that often appear in “they’re back” posts, CJC-1295 and ipamorelin, were not on the July agenda at all.

The community read the July meeting more carefully than the headlines did. In the posts on X that our community-insights data collected that month, users repeatedly stressed that the review was about access, not about whether the peptides work, and that it was not an approval vote.

Can you buy peptides over the counter?

Not as approved medicines: none of the substances in the table is sold as an FDA-approved over-the-counter drug for the uses people discuss. The status lines describe the two routes you will actually see, compounded prescriptions sold by some telehealth providers and products labeled “research use only.” Topical skin-care products that contain GHK-Cu are cosmetics, a separate category from the injectable form in the table. Our pages about substances that are sold online carry a labeled “Where it’s sold” card, kept separate from the editorial text, for readers who want to see one of those listings.

What about GLP-1 medications and testosterone?

They follow different rules from the peptides above and are covered on the sites that specialize in them. For how branded and compounded semaglutide and tirzepatide compare, see Modern Weight Medicine’s branded versus compounded GLP-1 guide. Testosterone is a controlled substance with its own telehealth rules, explained in TRT Clarity’s guide to getting TRT online without an in-person visit.

How is this page kept current?

We recheck every line monthly against the FDA’s Category 2 page, the eCFR bulks list, current FDA labels and maker statements, and sooner if FDA publishes a proposed rule on the bulks list. The date at the top of the table is the date of the last check. If a line here and a line on another page ever disagree, this page is the one we update first.

Educational information only, not medical or legal advice. Statuses are federal and current as of October 12, 2026; state law may differ.